Fortress Biotech, Inc. (FBIO)
| Market Cap | 82.38M +52.6% |
| Revenue (ttm) | 66.16M +14.5% |
| Net Income | 119.20M |
| EPS | 3.86 |
| Shares Out | 33.22M |
| PE Ratio | 0.64 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 824,579 |
| Open | 2.410 |
| Previous Close | 2.410 |
| Day's Range | 2.410 - 2.619 |
| 52-Week Range | 1.660 - 4.530 |
| Beta | 1.16 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+343.55%) |
| Earnings Date | May 14, 2026 |
About FBIO
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycl... [Read more]
Financial Performance
In 2025, Fortress Biotech's revenue was $63.26 million, an increase of 9.69% compared to the previous year's $57.68 million. Losses were -$1.88 million, -96.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price target is $11.0, which is an increase of 343.55% from the latest price.
News
Fortress Biotech price target raised to $5 from $4.50 at Alliance Global
Alliance Global raised the firm’s price target on Fortress Biotech (FBIO) to $5 from $4.50 and keeps a Buy rating on the shares, citing increased value from its cash balance…
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 mill...
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position inc...
Fortress Biotech Earnings Call Transcript: Q1 2026
Q1 2026 saw 21% revenue growth to $16M, led by EMROSI's strong performance and improved profitability. EMROSI prescriptions and revenue per script rose, with expanded payer access and new product launches planned to drive further growth.
Fortress Biotech Quarterly report: Q1 2026
Fortress Biotech has published its Q1 2026 quarterly earnings report on May 13, 2026.
Fortress Biotech Earnings release: Q1 2026
Fortress Biotech released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
Fortress Biotech Proxy statement: Proxy filing
Fortress Biotech filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Fortress Biotech Proxy statement: Proxy filing
Fortress Biotech filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Fortress Biotech Slides: Corporate presentation
Fortress Biotech has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100 mill...
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 ...
Fortress Biotech Earnings release: Q4 2025
Fortress Biotech released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of t...
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Appro...
Fortress Biotech Slides: Corporate presentation
Fortress Biotech has posted slides in relation to its latest quarterly earnings report, which was published on March 19, 2026.
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium ente...
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M
Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Re...
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium ente...
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWS...
Fortress Biotech, Cyprium announce FDA approval of ZYCUBO
Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, announced that the U.S. Food and Drug Administration has approved ZYCUBO for the treatment of Menkes disease in pediatr...
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium